Table 2.

Efficacy (RECIST 1.1 and clinical progression) per investigator assessment in ITT patients, by platinum status

	Platinum-resistant relapse N = 41	Platinum-sensitive relapse N = 33
Non-progression rate (%), median [90% CI]	3 months	6 months
All patients	69.8 [55.9–80.0]	43.8 [29.0–57.4]
BRCA1/2mut	N = 4	N = 11
	50.0 [10.3–80.9]	40.0 [15.9–63.3]
BRCA1/2wt / missing status	N = 37	N = 22
	72.2 [57.8–82.4]	45.5 [27.7–61.6]
Best overall response (confirmed)*
Complete response	0	1 (3%)
Partial response	11 (28%)	11 (34%)
Stable disease	18 (46%)	16 (50%)
Progressive disease	10 (26%)	4 (13%)
Not evaluable	2	1
Objective response rate (%) [95% CI]*	11 (28%) [15–45]	12 (38%) [21–56]
Median PFS, in months [95% CI]	4.1 [3.5−5.9]	4.9 [2.9−7.0]
Median OS, in months [95% CI]	18.8 [9.6 - NR]	18.5 [15.6 - NR]

NR not reached

*In evaluable patients